共 8 条
[1]
Effect of atorvastatin on plasminogen activator in hibitor type-1synthesisin human mon-ocytes/macrophages. Lopez S,Peiretti F,Bonardo B,et al. Journal of Cardiovascular Pharmacology . 2001
[2]
3-Hydroxy-3-methyl-glutaryl CoAreductase inhibitors prevent high glucose-indluced proliferation of mesangial cells via modulation of Rho GTPase/p2l signaling pathway:Implications for diabetic nephropathy. Danesh FR,Sadeghi MM,Amro N,et al. Proceedings of the National Academy of Sciences of the United States of America . 2002
[3]
Regulation of connective tissue growth factor(ccn2;ctgf)gene expression in human mesangial cells:modulation by HMG-CoAreductase in-hibitors(statins). Goppelt-struebe M,Halhn A,Iwanci w D,et al. Molecular Pathology . 2001
[4]
First United Kingdom Heart and Renal Protection(UK-HARP-I)study:biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Baigent C,Landray M,Leaper C,et al. American Journal of Kidney Diseases . 2005
[5]
Simvastatin attenuatas oxidant-induced mitochondrial dysfunction in cardiac myocytes. Jone SP,Teshima Y,Akao M,et al. Circulation Research . 2003
[6]
Cerivastatin,ahydroxymethylglutaryl coenzyme a reductase inhibitor,im-proves endothelial functionin elderly diabetic patients within3days. Sunekawa T,Hayash i T,Kano H,et al. Circulation . 2001
[7]
Effects of HMG-CoA-reductase inhibitors on survial in type2diabetes patients with end stage diabetic nephropathy. Gotz AK,Boger CA,Hirschmann C,et al. European Journal of Medical Research . 2005
[8]
Pleiotropic effects of HMG-CoAreductase inhibitors. Werner N,Nickenig G,Laufs U. Basic Research In Cardiology . 2002